# Chung H Kok

List of Publications by Year
in descending order

| | | | |
|---|---|---|---|
| 57<br>papers | 1,325<br>citations | 471061<br>17<br>h-index | 360668<br>35<br>g-index |
| 57<br>all docs | 57<br>docs citations | 57<br>times ranked | 2987<br>citing authors |

| # | Article | IF | Citations |
|---|---------|----|-----------| 
| 1 | Editorial: Molecular Mechanisms of Multiple Myeloma. Frontiers in Oncology, 2022, 12, 870123. | 1.3 | 1 |
| 2 | Outcomes following venetoclax–based treatment in therapy–related myeloid neoplasms. American Journal of Hematology, 2022, 97, 1013-1022. | 2.0 | 7 |
| 3 | RNA-Based Targeted Gene Sequencing Improves the Diagnostic Yield of Mutant Detection in Chronic Myeloid Leukemia. Journal of Molecular Diagnostics, 2022, 24, 803-822. | 1.2 | 2 |
| 4 | CKLF and IL1B transcript levels at diagnosis are predictive of relapse in children with pre–B–cell acute lymphoblastic leukaemia. British Journal of Haematology, 2021, 193, 171-175. | 1.2 | 2 |
| 5 | Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells. Frontiers in Cell and Developmental Biology, 2021, 9, 655201. | 1.8 | 7 |
| 6 | Clinical impact of *NPM1*-mutant molecular persistence after chemotherapy for acute myeloid leukemia. Blood Advances, 2021, 5, 5107-5111. | 2.5 | 25 |
| 7 | Distinct Senescent Bone Marrow Microenvironment in Therapy-Related Myeloid Neoplasms. Blood, 2021, 138, 2585-2585. | 0.6 | 1 |
| 8 | Highly Sensitive Droplet Digital PCR to Identify CML Patients with a High Probability of Achieving Treatment-Free Remission. Blood, 2021, 138, 2559-2559. | 0.6 | 0 |
| 9 | COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study. Blood, 2021, 138, 634-634. | 0.6 | 5 |
| 10 | Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia, 2020, 34, 1052-1061. | 3.3 | 39 |
| 11 | Integrated Bioinformatics Analysis Reveals Key Candidate Genes and Pathways Associated With Clinical Outcome in Hepatocellular Carcinoma. Frontiers in Genetics, 2020, 11, 814. | 1.1 | 11 |
| 12 | Successful treatment–free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. British Journal of Haematology, 2020, 191, 433-441. | 1.2 | 52 |
| 13 | COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study. Blood, 2020, 136, 46-47. | 0.6 | 17 |
| 14 | The Natural History of NPM1MUT Measurable Residual Disease (MRD) Positivity after Completion of Chemotherapy in Acute Myeloid Leukemia (AML). Blood, 2020, 136, 25-27. | 0.6 | 4 |
| 15 | Therapy-Related Myeloid Neoplasm Has a Distinct Pro-Inflammatory Bone Marrow Microenvironment and Delayed DNA Damage Repair. Blood, 2020, 136, 37-38. | 0.6 | 0 |
| 16 | Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances, 2019, 3, 1610-1621. | 2.5 | 27 |
| 17 | A Combination of CD302 gene Expression and 3-Months BCR-ABL1 Level Predicts Inferior Achievement of Deep Molecular Response in CP-CML Patients Treated with Imatinib. Blood, 2019, 134, 663-663. | 0.6 | 3 |
| 18 | Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. British Journal of Cancer, 2018, 118, 1000-1004. | 2.9 | 28 |

| # | Article | IF | Citations |
|---|---------|-----|-----------|
| 19 | Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia, 2018, 32, 2572-2579. | 3.3 | 66 |
| 20 | Co-fuse: a new class discovery analysis tool to identify and prioritize recurrent fusion genes from RNA-sequencing data. Molecular Genetics and Genomics, 2018, 293, 1217-1229. | 1.0 | 0 |
| 21 | Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant *BCR-ABL1*+ cell lines. Oncotarget, 2018, 9, 34735-34747. | 0.8 | 12 |
| 22 | Integration of Multiple Bioassays Using Machine Learning to Identify High-Risk CP-CML Patients Treated with Frontline Imatinib. Blood, 2018, 132, 1728-1728. | 0.6 | 1 |
| 23 | Increased peroxisome proliferator-activated receptor Î³ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica, 2017, 102, 843-853. | 1.7 | 12 |
| 24 | miR-155 as a potential target of IL-3 signaling in primary AML cells. Leukemia Research, 2017, 57, 57-59. | 0.4 | 6 |
| 25 | High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica, 2017, 102, e490-e493. | 1.7 | 52 |
| 26 | Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Letters, 2017, 408, 92-101. | 3.2 | 23 |
| 27 | A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia. Journal of Molecular Diagnostics, 2017, 19, 711-721. | 1.2 | 7 |
| 28 | A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. Cancer Genetics, 2017, 216-217, 86-90. | 0.2 | 10 |
| 29 | In Vitro Modeling of Ph-like ALL Fusions Identifies Novel Kinase-Domain Mutations As Mode of TKI-Resistance - Implications for Targeted Therapy. Blood, 2016, 128, 3957-3957. | 0.6 | 1 |
| 30 | PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. Journal of Hematology and Oncology, 2015, 8, 106. | 6.9 | 29 |
| 31 | High Prevalence of Relapse in Australian Children with Ph-like Acute Lymphoblastic Leukemia Despite Risk Adapted Treatment. Blood, 2015, 126, 1419-1419. | 0.6 | 1 |
| 32 | A 20 Gene Expression Signature That Predicts Early Molecular Response Failure in Chronic Phase CML Patients Treated with Frontline Imatinib. Blood, 2015, 126, 596-596. | 0.6 | 1 |
| 33 | High Peroxisome Proliferator-Activated Receptor-Gamma (PPARÎ³) Transcriptional Activity Reduces Active Influx of Imatinib and Kinase Inhibition in CML Cells. Blood, 2015, 126, 2770-2770. | 0.6 | 0 |
| 34 | Interleukin-3-mediated regulation of Î²-catenin in myeloid transformation and acute myeloid leukemia. Journal of Leukocyte Biology, 2014, 96, 83-91. | 1.5 | 13 |
| 35 | Modeling Ponatinib Resistance in BCR-ABL1+ Cell Lines: Implications for Ponatinib Resistance in TKI-Resistant and TKI-naïve Patients. Blood, 2014, 124, 4515-4515. | 0.6 | 1 |
| 36 | Identification of an Epithelial-to-Mesenchymal Transition (EMT)-like Programme in t(4;14)-Positive Multiple Myeloma Reveals Novel Targets for Therapeutic Intervention. Blood, 2014, 124, 647-647. | 0.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|---|---------|----|-----------|
| 37 | Whole Exome Sequencing of Acute Myeloid Leukaemia Patients Identifies Somatic and Germline Mutations in Fanconi Anaemia Genes. Blood, 2014, 124, 698-698. | 0.6 | 0 |
| 38 | High Plasma Levels of TGF-β and IL-6 at Diagnosis Predict Early Molecular Response Failure and Transformation in CML. Blood, 2014, 124, 1788-1788. | 0.6 | 1 |
| 39 | The preferential occurrence of *FLT3*‐TKD mutations in inv(16) AML and impact on survival outcome: a combined analysis of 1053 core‐binding factor AML patients. British Journal of Haematology, 2013, 160, 557-559. | 1.2 | 11 |
| 40 | Methylation of *KLF5* contributes to reduced expression in acute myeloid leukaemia and is associated with poor overall survival. British Journal of Haematology, 2013, 161, 884-888. | 1.2 | 18 |
| 41 | HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. Oncotarget, 2013, 4, 1933-1947. | 0.8 | 48 |
| 42 | Role Of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) and Its Ligands In The Regulation Of Functional OCT-1 Activity In CML Cells. Blood, 2013, 122, 1470-1470. | 0.6 | 0 |
| 43 | Genome-wide gene expression profiling identifies overlap with malignant adrenocortical tumours and novel mechanisms of inefficient steroidogenesis in familial ACTH-independent macronodular adrenal hyperplasia. Endocrine-Related Cancer, 2012, 19, L19-L23. | 1.6 | 6 |
| 44 | Ecotopic viral integration site 1 (EVI1) regulates multiple cellular processes important for cancer and is a synergistic partner for FOS protein in invasive tumors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2168-2173. | 3.3 | 74 |
| 45 | The GM-CSF receptor utilizes β-catenin and Tcf4 to specify macrophage lineage differentiation. Differentiation, 2012, 83, 47-59. | 1.0 | 23 |
| 46 | The granulocyte-associated transcription factor Krüppel-like factor 5 is silenced by hypermethylation in acute myeloid leukemia. Leukemia Research, 2012, 36, 110-116. | 0.4 | 28 |
| 47 | p53-Dependent Transcriptional Responses to Interleukin-3 Signaling. PLoS ONE, 2012, 7, e31428. | 1.1 | 6 |
| 48 | Global DNA Methylation Analysis Identifies Key Pathway Differences Between Poor (Low OCT-1 Activity) and Standard Risk CP-CML Patients At Diagnosis. Blood, 2012, 120, 3730-3730. | 0.6 | 0 |
| 49 | Methylation of the Proximal Promoter of GADD45A Is Common in Acute Myeloid Leukemia and Is Associated with Poor Survival.. Blood, 2012, 120, 2396-2396. | 0.6 | 0 |
| 50 | Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nature Genetics, 2011, 43, 1012-1017. | 9.4 | 524 |
| 51 | Differential Lineage Involvement Between Very Low and Higher OCT-1 Activity Chronic-Phase CML Patients. Blood, 2011, 118, 1675-1675. | 0.6 | 18 |
| 52 | Non-Steroidal Anti-Inflammatory Drugs and Imatinib; Drug Interactions That May Impact Efficacy,. Blood, 2011, 118, 3501-3501. | 0.6 | 0 |
| 53 | Methylation of a Single CpG in the GADD45A Proximal Promoter Is Associated with Poor Survival in Acute Myeloid Leukemia,. Blood, 2011, 118, 3540-3540. | 0.6 | 0 |
| 54 | GATA2 is a New Predisposition Gene for Familial Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 2010, 116, LBA-3-LBA-3. | 0.6 | 10 |

| # | Article | IF | Citations |
|---|---------|----|-----------|
| 55 | Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood, 2009, 114, 4859-4870. | 0.6 | 52 |
| 56 | Genetic regulators of myelopoiesis and leukemic signaling identified by gene profiling and linear modeling. Journal of Leukocyte Biology, 2006, 80, 433-447. | 1.5 | 37 |
| 57 | Highly sensitive droplet digital polymerase chain reaction for <i> <scp>BCR</scp> :: </i> <scp> <i>ABL1</i> messenger RNA </scp> identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment–free remission. British Journal of Haematology, 0, , . | 1.2 | 2 |